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Abstract 
Background: Intensivists’ clinical decision making pursues two main goals for patients: to decrease mortality and to 
improve quality of life and functional status in survivors. Patient‑important outcomes are gaining wide acceptance in 
most fields of clinical research. We sought to systematically review how well patient‑important outcomes are reported 
in published randomized controlled trials (RCTs) in critically ill patients.
Methods: Literature search was conducted to identify eligible trials indexed from January to December 2013. Articles 
were eligible if they reported an RCT involving critically ill adult patients. We excluded phase II, pilot and physiological 
crossover studies. We assessed study characteristics. All primary and secondary outcomes were collected, described 
and classified using six categories of outcomes including patient‑important outcomes (involving mortality at any time 
on the one hand and quality of life, functional/cognitive/neurological outcomes assessed after ICU discharge on the 
other).
Results: Of the 716 articles retrieved in 2013, 112 RCTs met the inclusion criteria. Most common topics were 
mechanical ventilation (27%), sepsis (19%) and nutrition (17%). Among the 112 primary outcomes, 27 (24%) were 
patient‑important outcomes (mainly mortality, 21/27) but only six (5%) were patient‑important outcomes besides 
mortality assessed after ICU discharge (functional disability = 4; quality of life = 2). Among the 598 secondary out‑
comes, 133 (22%) were patient‑important outcomes (mainly mortality, 92/133) but only 41 (7%) were patient‑impor‑
tant outcomes besides mortality assessed after ICU discharge (quality of life = 20, functional disability = 14; neuro‑
logical/cognitive performance = 5; handicap = 1; post‑traumatic stress = 1). Seventy‑three RCTs (65%) reported at 
least one patient‑important outcome but only 11 (10%) reported at least one patient‑important outcome besides 
mortality assessed after ICU discharge.
Conclusion: Patient‑important outcomes are rarely primary outcomes in RCTs in critically ill patients published in 
2013. Among them, mortality accounted for the majority. We promote the use of patient‑important outcomes in criti‑
cal care trials.
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Background
The paternalistic model of patient care has also encom-
passed the field of research in critical care for many years. 
To change this paradigm, some clinicians and research-
ers recently advocated for “the patient at the center” of 
medical decision making. They suggested recommending 
interventions, not when the magnitude of the effect was 
“clinically relevant” but when it was “patient important” 
[1]. The notion of “Patient-important” sheds light on the 
individual clinical encounter and the preeminence of 
patient’s value and preferences within that encounter. In 
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clinical research, a patient-important outcome has been 
previously defined as: “a characteristic or variable that 
reflect how a patient feels, functions or survives” [2, 3].
The principal goal of implementing intensive care units 
(ICU) was to save the life of critically ill patients (i.e., 
decrease mortality). This goal has been reached in many 
clinical situations such as septic shock or acute respira-
tory failure, owing to progress in symptomatic and etio-
logic treatments of shock and in mechanical ventilation 
[4, 5]. Although this goal remains a major objective for 
intensivists, other priorities have emerged. In particu-
lar, the importance of assessing mean and long-term 
outcome in survivors has been underlined [6]. Critical 
illness is indeed associated with a wide array of long-
term sequelae (physical and psychical) that impact func-
tional status and quality of life [7–11]. To account for 
the patient perspective, clinical decision making by ICU 
physicians now pursues the goal of improving mean and 
long-term outcomes in survivors in addition to increas-
ing their chance of survival. In case these goals cannot be 
reached, an alternative goal is improving the quality of 
death and dying in ICU.
In addition to mortality, assessing mean to long-term 
outcomes (after ICU and hospital discharge) could help 
define the usefulness of an intervention, taking into 
account what might be relevant and advantageous for the 
patients [12].
Numerous questions around outcomes used in rand-
omized controlled trials (RCTs) in critically ill patients 
led us to conduct this systematic review. The core ques-
tion of this review was guided, however, by patients’ pri-
orities. We chose to define patient-important outcomes 
according to these patients’ priorities (survival, quality of 
life, functional, cognitive and neurological performance 
assessed after ICU discharge) as it has been done in other 
fields such as diabetes [13].
The main objective of this systematic review was to 
investigate whether RCTs in critically ill patients pub-
lished in 2013 assess the patient-important outcomes.
Methods
To perform the systematic review on the 1-year period 
of 2013, we followed the PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis) state-
ment guidelines [14].
Outcome classification
Our outcome classification was developed according to 
previous work on patient-important outcome in various 
medical domains [3, 13, 15].
A scientific committee [including three intensivists 
(SG, J-DR and DD) and 1 methodologist (FT) particularly 
involved in designing and conducting RCTs in critically 
ill patients] established a classification of outcome cat-
egories relevant to ICU trials.
The experts identified six outcome categories:
Patient-important outcomes that included two entities: 
on the one hand, mortality at any time and on the other, 
quality of life, functional/cognitive/neurological out-
comes assessed after ICU discharge.
Clinical outcomes in ICU and hospital organ fail-
ure, complication/adverse outcomes (for instance: drug 
induced skin reaction or hypotension during renal 
replacement therapy), healthcare-associated outcomes 
(nosocomial pneumonia, catheter-related infections), 
delirium, clinical events (such as venous thromboem-
bolism, myocardial infarction), pain (in ICU), anxiety 
(in ICU), conscience level, return to spontaneous circu-
lation, muscle strength/circumference, sleep duration, 
National Institute of Health Stroke Score (NIHSS) (for 
acute phase of stroke), clinical response to antibiotics, 
dyspnea (in ICU), noninvasive ventilation tolerance.
Biological/physiological/radiological outcomes such as 
brain natriuretic peptide (BNP), neutrophil gelatinase-
associated lipocalin (NGAL), total lung capacity, chest 
X-ray severity score.
Care provider decision-related outcomes e.g., mechani-
cal ventilation duration, length of stay, antibiotic 
exposure, volume of fluid resuscitation, intubation or 
reintubation, number of gastric tubes for aspiration, 
sedation exposure (dose/time), renal replacement ther-
apy, ICU readmission, noninvasive ventilation, trache-
ostomy, transfusion, use of a prokinetic agent, need for 
surgery, dose of local anesthesia, hospital discharge 
disposition.
Care performance outcomes care procedure quality and 
noise/light exposure.
Other outcomes family satisfaction, physician/nurse or 
other provider satisfaction, cost/charges, withholding/
withdrawal of care, patient judgment about his readiness 
to discharge, workload for staff team, compliance to a 
care protocol, medicolegal conflict.
Besides, for primary outcomes, we defined a “surrogate 
outcome” as an outcome measuring a substitute for some 
other variable (e.g., a biomarker intended to substitute 
for a clinical endpoint) [2].
Article eligibility criteria
Articles were eligible if they met the following criteria: 
article published between January 2013 and Decem-
ber 2013; reporting an RCT involving critically ill adult 
patients (i.e., adults hospitalized in ICU); written in 
English.
We considered only the first report of the trial results 
and trial extension follow-up, i.e., we excluded articles 
reporting post hoc analyses and sub-analyses of RCTs. 
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Indeed, our aim was to focus on the RCTs’ initial objec-
tive. We also excluded phase II studies, pilot studies and 
physiological crossover studies because studies at this 
stage of clinical research are expected to explore mainly 
physiological and feasibility outcomes.
Search strategy and article selection
Main literature search (for the January 2013 to Decem-
ber 2013 period) was conducted on the July 16, 2014, in 
MEDLINE (via Pubmed®) to identify eligible articles 
indexed between January 2013 and December 2013. The 
search strategy relied on two algorithms, one dedicated 
to articles indexed with Mesh terms and the other dedi-
cated to articles not indexed (at the time of the search), 
using exclusively free text. Terms related to intensive 
care were combined with terms related to RCTs. Details 
regarding the literature search strategy and the terms 
used are provided in Additional file 1.
Two senior intensivists (SG and JM) independently 
screened the titles and abstracts for the eligibility criteria, 
to identify articles to be read in full text. Definite article 
selection was only achieved after examination of the full 
text confirmed that inclusion criteria were met.
Data collection
A standardized extraction form (available from the corre-
sponding author) was established from a literature review 
and a priori discussion. This extraction form was pre-
tested by two authors (SG and JM) independently, in a set 
of ten articles. This test enabled to identify items need-
ing rewording to avoid any confusion. Disagreements 
were discussed with an epidemiologist (last author, FT), 
to ensure similar understanding. Once all litigious points 
were settled, two reviewers (SG and JM) independently 
extracted the following data from the selected articles 
(using the full text and the Additional file 1): general data 
(funding source, geographical origin, topic, number of 
centers), methods (intervention assessed, study design, 
randomization design), quality assessment (by use of 
the risk of bias tool [16]), trial characteristics (inclu-
sion period, length of follow-up, number of randomized 
patients) and outcomes (time from randomization to 
assessment for primary outcome, type and characteristic 
of all outcomes, see paragraph above).
For all articles included in the systematic review, disa-
greements between the two reviewers (SG and JM) were 
resolved by consensus. In case of persistent disagree-
ment, arbitration by a third reviewer (FT) settled the 
discrepancy.
Statistical analyses
A 1-year time frame was chosen because it yielded a con-
venient study sample. Because of the significant lag in 
study indexation, the closest complete year available at 
the time of the literature search was 2013.
Continuous variables are described with median and 
interquartile range (IQR). Categorical variables are 
described with frequencies and percentages. Distribution 
of outcomes into the six categories (patient-important 
outcomes, clinical outcomes, bio/physio/radio outcomes, 
care provider decision-related outcomes, care perfor-
mance outcomes and others outcomes) is presented as 
radar plot. For primary and secondary outcomes, dis-
tribution is presented for all outcomes and according to 
three major topics.
Trial characteristics associated with the presence of at 
least one patient-important outcome (primary or sec-
ondary outcome) were identified in univariate analysis, 
using Chi-square test or Fisher’s test for categorical vari-
ables and Student’s test or Wilcoxon’s test for continuous 
variables.
Inter-reviewer agreement was measured by the kappa 
statistic for the following categorical variables: funding 
source, geographical origin, intervention assessed, unit of 
randomization and primary outcome category.
Statistical analysis was performed with GraphPad 
Prism 5 (GraphPad Software, San Diego, USA) and SAS 
version 9.3 (SAS Institute Inc, Cary, NC).
Results
Selection of articles and inter‑reviewer agreement
The electronic search identified 716 articles. Four hun-
dred and eighty were excluded on the basis of the title 
and abstract, and 124 after reading the full text. A total of 
112 articles reporting RCTs in critically ill patients were 
finally included and analyzed (see Fig. 1 for PRISMA flow 
diagram).
Inter-reviewer agreement before consensus for cat-
egorical variables was very good [17]: The median kappa 
value was 0.89 [0.83–0.95] for funding source, 0.99 [0.96–
1.00] for geographical origin, 0.83 [0.68–0.99] for unit of 
randomization and 0.95 [0.91–0.99] for primary outcome 
category; and good for intervention assessed (median 
kappa 0.74 [0.65–0.82]).
Characteristics of the 112 RCTs
Table  1 summarizes RCTs characteristics. Mechanical 
ventilation (27%), sepsis (18%) and nutrition (17%) were 
the most common topics of these trials. Therapeutic 
strategy (41%), drug (33%) and device (11%) evaluation 
were the most frequent types of intervention.
Follow-up period was defined until a fixed time point 
for 44 (39%) RCTs (median [IQR] 3 [1–6] months of fol-
low-up), until ICU discharge for 14 (12%) RCTs and until 
hospital discharge for 15 (13%) RCTs. Follow-up period 
was unclear for 39 (35%) RCTs.
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Quality assessment
Quality of the trials using the risk of bias tool is shown in 
Fig. 2. The absence of blinding of allocated intervention 
was the most frequent methodological component intro-
ducing a high risk of bias.
Primary outcomes
Seventy-three (65%) RCTs assessed the primary outcome 
after a median [IQR] fixed time point of 7 [2–28] days 
(from randomization) and only 13 (12%) assessed the pri-
mary outcome beyond 30 days (Fig. 3). The other RCTs 
assessed the primary outcome at ICU discharge (n = 25, 
22%) or hospital discharge (n = 9, 8%). Five (4%) did not 
specify the time from randomization to primary outcome 
assessment.
Among the 112 primary outcomes, 27 (24%) were 
patient-important outcomes. Most of them were mortal-
ity (21/27, 78%) and only 6/27 (22%) were quality of life, 
functional/cognitive/neurological outcomes assessed 
after ICU discharge (functional disability = 4; quality of 
life = 2).
Among the 21 mortality outcomes, 18 were assessed 
after a fixed time point of 28 [28–60] days. The other 
three were assessed at ICU discharge. Among the 
six quality of life, functional/cognitive/neurological 
outcomes, two were assessed at hospital discharge and 
four after a fixed time point (6, 12, 12, 14 months). Fig-
ure 4 shows the distribution of the 112 primary outcomes 
and according to the three major topics (mechanical ven-
tilation, sepsis, nutrition). Besides, 45 (40%) primary out-
comes were surrogate endpoints.
Secondary outcomes
Among 598 secondary outcomes identified, 133 (22%) 
were patient-important outcomes. Most of them were 
mortality (92/133, 69%) and only 41 (31%) were quality of 
life, functional/cognitive/neurological outcomes assessed 
after ICU discharge (quality of life = 20, functional dis-
ability  =  14; neurological/cognitive performance  =  5; 
handicap = 1; post-traumatic stress = 1).
Among the 92 mortality outcomes, 43 were assessed 
after a fixed time point of 28 [28–90] days. The others 
were assessed at ICU discharge (n  =  26) or at hospital 
discharge (n  =  23). Among the 41 quality of life, func-
tional/cognitive/neurological outcomes, 37 were assessed 
at a fixed time point of 365 [319–380] days and four at 
hospital discharge.
Figure  5 shows the distribution of the 598 second-
ary outcomes and according to the three major topics 
(mechanical ventilation, sepsis, nutrition).
Arcles idenfied  
from electronic search





No ICU paent 138
Studies protocol/Methodology 17
Case report 3
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Meta-analysis/review 6
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Fig. 1 PRISMA flow diagram
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Table 1 Characteristics of RCTs in critically ill adult patients
Characteristic RCTs without any  
patient‑important  
outcomes no. (%)
RCTs reporting at least  





Public 14 (36) 42 (57)
Industry 6 (15) 8 (11)
Both public and private 18 (46) 10 (14)
Not reported or unclear 1 (3) 13 (18)
Geographical area
Europe 12 (31) 34 (47)
Asia 18 (46) 19 (26)
North America 4 (10) 16 (22)
Oceania 3 (8) 9 (12)
South America 2 (5) 8 (11)
Africa 0 (0) 5 (7)
International (>1 country) 0 (0) 18 (25)
Number of center(s) 0.005
Monocenter 29 (74) 33 (45)
Multicenter 8 (21) 38 (52)
Unclear 2 (5) 2 (3)
Sample size 0.01
<50 16 (41) 16 (22)
50–100 7 (18) 14 (19)
100–150 6 (15) 5 (7)
150–500 7 (18) 20 (27)
>500 3 (8) 18 (25)
Topic of the studya
Mechanical ventilation 14 (36) 16 (22) 0.011
Sepsis 2 (5) 19 (26) 0.007
Nutrition 5 (13) 14 (19) 0.39
Infection 8 (21) 10 (14)
Hemodynamics 2 (5) 4 (5)
ARDS 2 (5) 7 (10)
Cardiac arrest 2 (5) 4 (5)
Trauma 3 (8) 3 (4)
Sedation 2 (5) 1 (1)
Acute kidney injury 1 (3) 3 (4)
Pain 2 (5) 2 (3)
Neurocritical care 1 (3)




Metabolic disorder 1 (3)
Burns 0 (0) 1 (1)
ECMO 0 (0) 1 (1)
Electric muscle stimulation 1 (3)
Music 1 (3)
Type of intervention 0.37
Therapeutic strategy 14 (36) 32 (44)
Drug 13 (33) 24 (33)
Device 6 (15) 7 (10)
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Table 1 continued
Characteristic RCTs without any  
patient‑important  
outcomes no. (%)
RCTs reporting at least  
one patient‑important  
outcome no. (%)
P value
Monitoring 2 (5) 1 (1)
Diagnostic strategy 0 (0) 4 (5)
Other 4 (10) 5 (7)
Unit of randomization 0.74
Patient 35 (90) 67 (92)
Service 2 (5) 3 (4)
Time 1 (3) 1 (1)
Other 1 (3) 2 (3)
Type of trial 1.00
Superiority 38 (97) 70 (96)
Equivalence or non‑inferiority 1 (3) 3 (4)
Follow-up
Fixed time point 22 (56) 41 (56)
Median months [IQR] 0.5 [0.5–1] 3 [1–9] 0.0002
ICU 7 (18) 7 (10)
Hospital 3 (8) 12 (16)
Unreported 7 (18) 13 (18)
The numbers in parentheses mean the percentage; ECMO: extracorporeal membrane oxygenation
A study can appear in more than one row for geographical area
a One study could have more than one topic
0% 20% 40% 60% 80% 100%
Other problems with high risk of bias
Free of suggeson selecve outcome
reporng
Incomplete outcome data adequately
addressed
Blinding of allocated intervenon
Allocaon concealment
Random sequence generaon
Low risk of bias
Unclear risk of bias
High risk of bias
Fig. 2 RCTs quality assessment by risk of bias tool [16]. Methodological quality of the trials included in the systematic review assessed by six points: 
random sequence generation, allocation concealment, blinding of allocation intervention, incomplete data adequately addressed, free of sugges‑
tion selective outcome reporting and other problems. Horizontal axis represents the ratio (%) distribution among “low risk of bias” (green), “high risk 
of bias” (red) and “unclear risk of bias” (yellow)
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Trial characteristics associated with the presence of at least 
one patient‑important outcome (primary or secondary)
Among the 112 RCTs, 73 (65%) reported at least one 
patient-important outcome (primary or secondary out-
comes) but only 11 (10%) reported at least one quality of 
life, functional/cognitive/neurological outcomes assessed 
after ICU discharge. Characteristics of these RCTs are 
provided in Table 1.
Discussion
We found that, during the 1-year survey period of RCTs 
performed in critically ill patients, a minority of out-
comes used in these RCTs were patient-important out-
comes. They accounted for 24 and 22% of primary and 
secondary outcomes, respectively. Mortality accounted 





















Fig. 3 Time from randomization to assessment of primary outcome. 
This figure represents the distribution of the time from randomization 
to assessment of primary outcome for the 73 RCTs that assessed the 


































Fig. 4 Distribution of primary outcomes. a Distribution of 112 
primary outcomes, percentage of primary outcomes by outcome cat‑
egory, b distribution of primary outcomes according to three major 
topics (mechanical ventilation, sepsis and nutrition), percentage of 

































Fig. 5 Distribution of secondary outcomes. a Distribution of 598 sec‑
ondary outcomes, percentage of secondary outcomes by outcome 
category, b distribution of secondary outcomes according to three 
major topics (mechanical ventilation, sepsis and nutrition), percent‑
age of secondary outcomes by outcome category
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outcomes, whereas other patient-important outcomes 
(such as quality of life, functional/cognitive/neuro-
logical outcomes assessed after ICU discharge) were 
scarcely used (7% of all outcomes). Moreover, only 10% 
of surveyed RCTs reported at least one patient-important 
outcome besides mortality (quality of life, functional/
cognitive/neurological outcomes assessed after ICU dis-
charge). This is at striking contrast with clinical decision 
making of ICU physicians, which is felt to be in line with 
these crucial outcomes. In addition, we were cautious 
to retain only those RCTs for which patient-important 
outcomes were reasonably expected. Indeed, studies for 
which patient-important outcomes were less likely to be 
present (phase II studies, pilot studies and physiological 
crossover studies) were not included.
Our study is the first to explore the place of patient-
important outcomes and how well they are reported in 
RCTs in critically ill patients. We derived the definition of 
patient-important outcome for critically ill patients from 
the definition used in other fields [3, 13, 15]. Mortality is 
obviously essential, and we considered that quality of life, 
functional/cognitive/neurological outcomes assessed after 
ICU discharge also qualified for patient-important out-
come. Indeed, the potential adverse consequences of an 
ICU stay are best evaluated after ICU discharge and even 
more after hospital discharge since critical illness is asso-
ciated with long-term sequelae. Survivors of critical care 
experience profound changes in their lives because of many 
forms of deficit in one or more domains [18] of physical 
[19, 20], psychological [11, 21, 22] or cognitive functioning 
[22–25]. These numerous symptoms led to define the new 
entity of “post-intensive care syndrome” [26].
This study is the first to use a definition of patient-
important outcomes for critically ill patients. This defini-
tion is open to criticism on two points. Firstly, it includes 
exogenous measures of symptoms that may not perfectly 
capture how patients feel or how symptoms impact their 
overall quality of life. We could have restricted the defi-
nition to patient-reported outcomes [27]. Nevertheless, 
doing this, the message of this study would have been 
the same. Indeed, among the 27 primary outcomes, 
which were patient-important outcomes, four were clas-
sified as functional disability and two of those were not 
patient-reported outcomes. Secondly, besides mortality 
outcomes, we chose to restrict the patient-important out-
comes to the post-ICU period (leaving out pain, anxiety 
and dyspnea which might have occurred during the ICU 
stay). However, in the present systematic review, “pain, 
anxiety and dyspnea in ICU” accounted for only two 
(1.8%) primary outcomes and four (0.7%) secondary out-
comes. If we had considered these outcomes as patient-
important outcomes, the results of this study would have 
been very similar.
To perform this systematic review, we developed an 
outcome classification relevant to the context of criti-
cal care, involving six categories (patient-important out-
comes, clinical outcomes in ICU and hospital, biological/
physiological/radiological outcomes, care provider deci-
sion-related outcomes, care performance outcomes and 
others). A systematic review is the first step to establish 
a core outcome set and our outcome classification could 
help researchers to clarify the place of patient-important 
outcomes in core outcome sets for future RCTs in criti-
cally ill patients. To date, there is no taxonomy of out-
comes studied in critically ill patients, nor core outcome 
set. This may cause inconsistencies in outcome reports 
and difficulties in comparing these outcomes across stud-
ies and to combine them in systematic reviews and meta-
analyses [28]. With the aim to facilitate the development 
and application of agreed standardized sets of outcomes, 
the Core Outcome Measures in Effectiveness Trials 
(COMET) initiative was initiated in [29]. In the field of 
critical care, the Core Outcomes in Ventilation Trials 
(COVenT) is in progress [30]. This systematic review can 
be the first step to develop other core outcome sets in 
other topics of critical care and to establish a core out-
come set involving patients’ opinion for future RCTs.
An inherent limitation of a systematic review of pub-
lished trials is that it is performed at a given period (here 
2013). The search led to identify 112 eligible RCTs, which 
provides a very large panel of ICU trials and thus robust 
information on the prevalence of patient-important out-
comes in RCTs in critically ill patients. Many system-
atic reviews rely issues on a 1-year literature search [31, 
32]. Our goal was to capture the most recent practices 
in trials as the literature on patient-important outcomes 
in other medical field and the growing interest for the 
patients’ perspective may have had an impact.
Patient-important outcomes are gaining wide accept-
ance in some fields of clinical research [33–35]. Addi-
tionally, a recent survey from 2036 patients with diabetes 
showed that most of them (>75%) chose patient-impor-
tant outcomes rather than HbA1c as their first choice 
for a trial primary outcome [36]. Patients understand the 
reality of their condition and disease’s impact on their 
lives better than physicians can do [37]. James Lind Alli-
ance in the UK [38, 39] and the Patient-Centered Out-
come Research Institute in the USA [40–43] showed 
the mismatch between questions patients and clinicians 
needed an answer for on the one hand and those that 
were investigated by researchers on the other. This led 
some opinion leaders to call for a patient revolution [44]. 
Patients who survive after a critical illness may experi-
ence many sequelae after ICU or hospital discharge. In 
our study, only 10% of RCTs reported at least one non-
mortality patient-centered outcome assessed after ICU 
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discharge. It seems therefore desirable that more long-
term outcomes be assessed in ICU studies.
Reasons explaining this small percentage of RCTs 
assessing patient-important outcomes and in particu-
lar the impressive scarcity of outcomes assessed after 
ICU discharge are diverse. One of them is the difficulty 
to ascertain mean and long-term follow-up of patients. 
The preference of researchers and funding agencies for 
rapidly obtained results favors short-term outcomes. 
This could be a shortcoming since paradoxical short- and 
long-term effects after certain interventions have been 
described [45, 46]. For instance, after acute myocardial 
infarction flecainide decreased arrhythmias but has been 
associated with increased mortality [45]. In critical ill-
ness, growth hormone improved nitrogen balance but 
has been also associated with increased mortality [47]. 
Moreover, many proposed short-term endpoints in criti-
cal care have not been formally evaluated for surrogacy 
[48] precluding any strong conclusion on the effect on 
patient-important outcomes. For example, acute organ 
dysfunction in ICU does not appear to have significant 
long-term implications for patient-important outcomes 
[49]. In our systematic review, we found that 40% of pri-
mary outcomes were surrogate endpoints.
To promote the assessment of patient-important out-
comes, patients’ follow-up should be extended but this 
can be hampered by logistical issues (organization of 
phone call, medical consultation, etc.) which can con-
siderably increase the costs of the study. As a result, we 
found that patients’ follow-up was short since only 12% 
of trials assessed primary outcomes beyond 30 days from 
randomization. Patient-important outcomes were ini-
tially promoted to evaluate outcomes of chronic diseases 
[13, 15] for which patients’ follow-up is easier to per-
form because the patient is cared for by the same medi-
cal team. This situation is quite different for critically ill 
patients who are often cared for by a different team after 
ICU discharge. The advent of post-ICU consultation [50] 
could foster a better assessment of patient-important 
outcomes by intensivists and researchers in the field.
Additionally, lengthy technical questionnaires are usu-
ally used to assess patient-reported outcomes (i.e., qual-
ity of life or functional status) after ICU discharge. This 
often leads to a high proportion of non-responders that 
renders interpretation more Difficult [51]. The question of 
the applicability to the ICU setting of the tools used is also 
raised by ICU experts: “Are existing instruments suitable 
for capturing important nuances of post-ICU sequelae or 
should disease-specific instruments be captured” [6].
The decisions intensivists make at the bedside aim at 
both saving lives and preserving—at best—their patients’ 
prior quality of life. Medical research and especially RCTs 
should help them to better evaluate the efficacy of their 
interventions (drug administration, therapeutic strategy 
implementation or device use) on these relevant issues.
 Our results indicate that outcomes of many RCTs 
remained too often centered on physiological criteria 
(oxygenation or hemodynamic stabilization for instance) 
or assessed mortality as sole outcome of importance for 
patients. This has two pitfalls: quality of life of survivors 
is not assessed, and given the noticeable improvement 
of vital prognosis in a number of ICU situations (ARDS 
for example), many interventional studies using mortality 
as primary outcome have been negative in recent years, 
mandating the use of alternative outcome measures, such 
as patient-important ones [48, 52, 53].
Conclusion
 Our study shows that only a small number of primary 
outcomes measures in recent RCTs performed in the 
ICU are patient-important outcomes. To better address 
patient needs, researchers should take the crucial post-
ICU period into account in the design of future RCTs. 
This is one of the challenges for future ICU research. This 
paradigm shift would be in the interest of patients.
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